JP6312332B2 - 糖尿病バイオマーカ - Google Patents
糖尿病バイオマーカ Download PDFInfo
- Publication number
- JP6312332B2 JP6312332B2 JP2015514216A JP2015514216A JP6312332B2 JP 6312332 B2 JP6312332 B2 JP 6312332B2 JP 2015514216 A JP2015514216 A JP 2015514216A JP 2015514216 A JP2015514216 A JP 2015514216A JP 6312332 B2 JP6312332 B2 JP 6312332B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- central memory
- therapy
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 45
- 239000000090 biomarker Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims description 74
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 71
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 57
- 238000002560 therapeutic procedure Methods 0.000 claims description 54
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 40
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 22
- 102100033467 L-selectin Human genes 0.000 claims description 22
- 238000005259 measurement Methods 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000000684 flow cytometry Methods 0.000 claims description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 88
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 208000023275 Autoimmune disease Diseases 0.000 description 37
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 32
- 108010075254 C-Peptide Proteins 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 229940125396 insulin Drugs 0.000 description 21
- 229960003697 abatacept Drugs 0.000 description 20
- 230000005784 autoimmunity Effects 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 230000007423 decrease Effects 0.000 description 17
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 208000001280 Prediabetic State Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000009104 prediabetes syndrome Diseases 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 102000006449 Class 8 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 description 6
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010185 immunofluorescence analysis Methods 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010076181 Proinsulin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001666 CD4-positive, alpha-beta memory T lymphocyte Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004296 naive t lymphocyte Anatomy 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Ecology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651144P | 2012-05-24 | 2012-05-24 | |
| US61/651,144 | 2012-05-24 | ||
| PCT/US2013/042627 WO2013177505A1 (en) | 2012-05-24 | 2013-05-24 | Diabetes biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027381A Division JP6761827B2 (ja) | 2012-05-24 | 2018-02-19 | 糖尿病バイオマーカ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520378A JP2015520378A (ja) | 2015-07-16 |
| JP2015520378A5 JP2015520378A5 (enExample) | 2016-11-24 |
| JP6312332B2 true JP6312332B2 (ja) | 2018-04-18 |
Family
ID=49621783
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514216A Active JP6312332B2 (ja) | 2012-05-24 | 2013-05-24 | 糖尿病バイオマーカ |
| JP2018027381A Expired - Fee Related JP6761827B2 (ja) | 2012-05-24 | 2018-02-19 | 糖尿病バイオマーカ |
| JP2020150183A Pending JP2021001899A (ja) | 2012-05-24 | 2020-09-07 | 糖尿病バイオマーカ |
| JP2022175993A Pending JP2023011814A (ja) | 2012-05-24 | 2022-11-02 | 糖尿病バイオマーカ |
| JP2024120652A Pending JP2024150702A (ja) | 2012-05-24 | 2024-07-25 | 糖尿病バイオマーカ |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027381A Expired - Fee Related JP6761827B2 (ja) | 2012-05-24 | 2018-02-19 | 糖尿病バイオマーカ |
| JP2020150183A Pending JP2021001899A (ja) | 2012-05-24 | 2020-09-07 | 糖尿病バイオマーカ |
| JP2022175993A Pending JP2023011814A (ja) | 2012-05-24 | 2022-11-02 | 糖尿病バイオマーカ |
| JP2024120652A Pending JP2024150702A (ja) | 2012-05-24 | 2024-07-25 | 糖尿病バイオマーカ |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130316375A1 (enExample) |
| EP (2) | EP3767295A1 (enExample) |
| JP (5) | JP6312332B2 (enExample) |
| KR (1) | KR102172285B1 (enExample) |
| CN (1) | CN104520707B (enExample) |
| AU (4) | AU2013266145A1 (enExample) |
| CA (1) | CA2874507A1 (enExample) |
| DK (1) | DK2856149T3 (enExample) |
| ES (1) | ES2810227T3 (enExample) |
| IN (1) | IN2014DN10259A (enExample) |
| MX (1) | MX357169B (enExample) |
| WO (1) | WO2013177505A1 (enExample) |
| ZA (1) | ZA201409006B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018116061A (ja) * | 2012-05-24 | 2018-07-26 | ディーエムノーモア リミテッド | 糖尿病バイオマーカ |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| CN113138279A (zh) | 2012-06-27 | 2021-07-20 | 法姆制药有限责任公司 | 融合蛋白组合物的应用 |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| WO2016103390A1 (ja) * | 2014-12-25 | 2016-06-30 | 株式会社日立製作所 | インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法 |
| CN105567851A (zh) * | 2016-02-29 | 2016-05-11 | 北京泱深生物信息技术有限公司 | 一种与糖尿病相关的分子标志物 |
| EP3433612B1 (en) * | 2016-03-22 | 2024-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits of assessing status, risk or prognosis of type 1 diabetes |
| CA3184157A1 (en) | 2020-06-26 | 2021-12-30 | Phaim Pharma Ltd | Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform |
| US20240277768A1 (en) | 2021-06-17 | 2024-08-22 | Tihamer Orban | Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1930415A4 (en) * | 2005-09-30 | 2009-05-13 | Univ Kyoto | DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC |
| US9176122B2 (en) * | 2008-03-24 | 2015-11-03 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
| US20100080784A1 (en) * | 2008-09-12 | 2010-04-01 | Torrey Pines Institute For Molecular Studies | Methods for treating cachexia and lymphopenia |
| US20130316375A1 (en) * | 2012-05-24 | 2013-11-28 | Orban Biotech Llc | Diabetes biomarkers |
-
2013
- 2013-03-14 US US13/803,581 patent/US20130316375A1/en not_active Abandoned
- 2013-05-24 EP EP20184212.7A patent/EP3767295A1/en active Pending
- 2013-05-24 KR KR1020147036002A patent/KR102172285B1/ko active Active
- 2013-05-24 AU AU2013266145A patent/AU2013266145A1/en not_active Abandoned
- 2013-05-24 JP JP2015514216A patent/JP6312332B2/ja active Active
- 2013-05-24 ES ES13794110T patent/ES2810227T3/es active Active
- 2013-05-24 EP EP13794110.0A patent/EP2856149B1/en active Active
- 2013-05-24 CN CN201380027247.6A patent/CN104520707B/zh not_active Expired - Fee Related
- 2013-05-24 CA CA2874507A patent/CA2874507A1/en active Pending
- 2013-05-24 WO PCT/US2013/042627 patent/WO2013177505A1/en not_active Ceased
- 2013-05-24 MX MX2014014348A patent/MX357169B/es active IP Right Grant
- 2013-05-24 DK DK13794110.0T patent/DK2856149T3/da active
-
2014
- 2014-12-02 IN IN10259DEN2014 patent/IN2014DN10259A/en unknown
- 2014-12-08 ZA ZA2014/09006A patent/ZA201409006B/en unknown
-
2016
- 2016-06-17 US US15/185,831 patent/US20160299128A1/en not_active Abandoned
-
2018
- 2018-02-19 JP JP2018027381A patent/JP6761827B2/ja not_active Expired - Fee Related
- 2018-12-28 US US16/235,556 patent/US20190137483A1/en not_active Abandoned
-
2019
- 2019-02-07 AU AU2019200824A patent/AU2019200824B2/en not_active Ceased
-
2020
- 2020-09-07 JP JP2020150183A patent/JP2021001899A/ja active Pending
-
2021
- 2021-04-28 AU AU2021202609A patent/AU2021202609A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022175993A patent/JP2023011814A/ja active Pending
-
2023
- 2023-04-27 US US18/140,214 patent/US20230333094A1/en not_active Abandoned
- 2023-08-31 AU AU2023222980A patent/AU2023222980A1/en active Pending
-
2024
- 2024-07-25 JP JP2024120652A patent/JP2024150702A/ja active Pending
-
2025
- 2025-04-10 US US19/175,610 patent/US20250237643A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018116061A (ja) * | 2012-05-24 | 2018-07-26 | ディーエムノーモア リミテッド | 糖尿病バイオマーカ |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150022878A (ko) | 2015-03-04 |
| JP2018116061A (ja) | 2018-07-26 |
| CN104520707A (zh) | 2015-04-15 |
| AU2019200824B2 (en) | 2021-06-24 |
| EP2856149A1 (en) | 2015-04-08 |
| US20160299128A1 (en) | 2016-10-13 |
| MX357169B (es) | 2018-06-28 |
| AU2019200824A1 (en) | 2019-04-04 |
| JP2024150702A (ja) | 2024-10-23 |
| AU2021202609A1 (en) | 2021-05-27 |
| JP6761827B2 (ja) | 2020-09-30 |
| EP3767295A1 (en) | 2021-01-20 |
| US20230333094A1 (en) | 2023-10-19 |
| EP2856149A4 (en) | 2016-06-01 |
| IN2014DN10259A (enExample) | 2015-08-07 |
| MX2014014348A (es) | 2015-06-05 |
| JP2021001899A (ja) | 2021-01-07 |
| KR102172285B1 (ko) | 2020-11-02 |
| US20130316375A1 (en) | 2013-11-28 |
| EP2856149B1 (en) | 2020-07-08 |
| JP2015520378A (ja) | 2015-07-16 |
| DK2856149T3 (da) | 2020-08-17 |
| AU2013266145A1 (en) | 2015-01-15 |
| ES2810227T3 (es) | 2021-03-08 |
| US20250237643A1 (en) | 2025-07-24 |
| JP2023011814A (ja) | 2023-01-24 |
| CA2874507A1 (en) | 2013-11-28 |
| CN104520707B (zh) | 2018-03-27 |
| ZA201409006B (en) | 2016-07-27 |
| US20190137483A1 (en) | 2019-05-09 |
| WO2013177505A1 (en) | 2013-11-28 |
| AU2023222980A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6312332B2 (ja) | 糖尿病バイオマーカ | |
| Couper et al. | ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. | |
| US20240409633A1 (en) | Methods and Compositions for Preventing Type 1 Diabetes | |
| WO2014043793A1 (en) | Cmpf as a biomarker for diabetes and associated methods | |
| Iwama et al. | Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors | |
| CN111065749B (zh) | 用于确定发展1型糖尿病的风险的方法 | |
| Aamodt et al. | The pathophysiology, presentation and classification of Type 1 diabetes | |
| Killestein et al. | Antibody‐mediated suppression of Vβ5. 2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial | |
| EP3247384B1 (en) | In vitro method of diagnosis of type 1 diabetes with insulin mimotopes | |
| Tizazu et al. | Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy | |
| Grönholm et al. | Novel diagnostic and therapeutic approaches for autoimmune diabetes—a prime time to treat insulitis as a disease | |
| Hosszúfalusi et al. | A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C‐peptide secretion, HLA‐DR and‐DQ status and autoantibody pattern | |
| US20100143919A1 (en) | In vitro assay for early diagnosis of diabetes mellitus type 1 | |
| McCormick | Alexandra Martin1, 4, Gail J. Mick, Heather M. Choat, Alison A. Lunsford, Hubert M. Tse 2, Gerald G. McGwin Jr. 3 & | |
| WO2025174781A1 (en) | Use of cardiac autoantibodies as a method to identify individuals at increased risk of developing cardiovascular events | |
| JP2024535635A (ja) | １型糖尿病の処置を予後予測するための方法 | |
| Ghosh | Yearbook of Diabetes 2017 | |
| Keymeulen et al. | Predictors of progression to Type 1 diabetes: preparing | |
| Bosch et al. | MINUTES OF THE 48th GENERAL ASSEMBLY OF THE EUROPE-AN ASSOCIATION FOR THE STUDY OF DIABETES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160524 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160524 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170704 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180118 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180319 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6312332 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |